Tabirafusp tedromer

N/A

Report date: 2024/08/23 09:47:26

First In Class

Base Information

Drug NameTabirafusp tedromer

Drug Alias NameKSI-501KSI-501ABC

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionInterleukin-6 inhibitorsVascular endothelial growth factor inhibitors

TargetsInterleukin-6Vascular endothelial growth factor

Therapy Area/IndicationsDiabetic macular oedemaUveitisWet age-related macular degeneration +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto Rico

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesKodiak Sciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesKodiak Sciences Inc

Inactive CompaniesN/A

Active IndicationsDiabetic macular oedemaWet age-related macular degenerationRetinal Diseases

Inactive IndicationsUveitis

Other Information

ATC CodeN/A